Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Hoepner

Showing results (51-60 of 130) with videos related to

Pageof 13
Sort By:
Brain and Behavior|May 5, 2022
No optical coherence tomography changes in premanifest Huntington's disease mutation carriers far from disease onsetRahel Dominique Schmid, Jana Remlinger, Mathias Abegg, et al.
Plos One|April 27, 2017
Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)Ruth Schneider, Barbara Bellenberg, Robert Hoepner, et al.
CNS Neuroscience & Therapeutics|December 8, 2022
Multiple sclerosis as a model to investigate SARS-CoV-2 effect on brain atrophyMichael Rebsamen, Christoph Friedli, Piotr Radojewski, et al.
Cells|September 26, 2020
c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune EncephalomyelitisMaud Bagnoud, Myriam Briner, Jana Remlinger, et al.
Frontiers in Human Neuroscience|June 30, 2022
Effect of Season of Birth on Hippocampus Volume in a Transdiagnostic Sample of Patients With Depression and SchizophreniaNora Schaub, Nina Ammann, Frauke Conring, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|July 20, 2018
Stroke admission outside daytime working hours delays mechanical thrombectomy and worsens short-term outcomeRobert Hoepner, Ralph Weber, Gernot Reimann, et al.
CNS Neuroscience & Therapeutics|October 15, 2016
Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple SclerosisMarkus Kinner, Robert Hoepner, Peter Klotz, et al.
Annals of the Rheumatic Diseases|July 21, 2021
Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting SystemMaximilian Pistor, Andreas G F Hoepner, Yanan Lin, et al.
Therapeutic Advances in Neurological Disorders|October 14, 2022
Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting SystemMaximilian Pistor, Robert Hoepner, Andreas G F Hoepner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2022
Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patientsChristoph Friedli, Franca Wagner, Helly Noemi Hammer, et al.
Pageof 13

Showing results (51-60 of 130) with videos related to

Sort By:
Pageof 13
Brain and Behavior|May 5, 2022
No optical coherence tomography changes in premanifest Huntington's disease mutation carriers far from disease onsetRahel Dominique Schmid, Jana Remlinger, Mathias Abegg, et al.
Plos One|April 27, 2017
Metabolic profiles by 1H-magnetic resonance spectroscopy in natalizumab-associated post-PML lesions of multiple sclerosis patients who survived progressive multifocal leukoencephalopathy (PML)Ruth Schneider, Barbara Bellenberg, Robert Hoepner, et al.
CNS Neuroscience & Therapeutics|December 8, 2022
Multiple sclerosis as a model to investigate SARS-CoV-2 effect on brain atrophyMichael Rebsamen, Christoph Friedli, Piotr Radojewski, et al.
Cells|September 26, 2020
c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune EncephalomyelitisMaud Bagnoud, Myriam Briner, Jana Remlinger, et al.
Frontiers in Human Neuroscience|June 30, 2022
Effect of Season of Birth on Hippocampus Volume in a Transdiagnostic Sample of Patients With Depression and SchizophreniaNora Schaub, Nina Ammann, Frauke Conring, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|July 20, 2018
Stroke admission outside daytime working hours delays mechanical thrombectomy and worsens short-term outcomeRobert Hoepner, Ralph Weber, Gernot Reimann, et al.
CNS Neuroscience & Therapeutics|October 15, 2016
Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple SclerosisMarkus Kinner, Robert Hoepner, Peter Klotz, et al.
Annals of the Rheumatic Diseases|July 21, 2021
Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting SystemMaximilian Pistor, Andreas G F Hoepner, Yanan Lin, et al.
Therapeutic Advances in Neurological Disorders|October 14, 2022
Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting SystemMaximilian Pistor, Robert Hoepner, Andreas G F Hoepner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 16, 2022
Leptomeningeal enhancement under different MS immunotherapies: A monocentric retrospective cohort study of 214 patientsChristoph Friedli, Franca Wagner, Helly Noemi Hammer, et al.
Pageof 13